Piers Ingram
CEO
Hummingbird Bioscience
Hummingbird Bioscience develops next-generation antibody-drug conjugates (ADCs) using proprietary linker-payload technologies to target cancer cells with high specificity. Their approach aims to provide effective treatment options for patients who do not respond to existing therapies, enhancing the potential for durable clinical responses.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$125MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many cancer patients do not respond to existing therapies, creating a need for more effective and targeted treatment options. Traditional antibody-drug conjugates (ADCs) may lack the specificity needed to selectively target cancer cells, leading to off-target effects and limited efficacy.
Solution
Hummingbird Bioscience is developing next-generation antibody-drug conjugates (ADCs) designed for precision medicine. Their approach utilizes proprietary linker-payload technologies to enhance the specificity of ADCs, ensuring they target cancer cells with greater accuracy. This targeted approach aims to improve treatment outcomes for patients who have not responded to current therapies, potentially leading to more durable clinical responses. The company focuses on targets in cancer with strong biological rationale and clinical validation, engineering precision therapies with the potential for deep and lasting responses.
Target Audience
The primary target audience includes cancer patients who have not responded to existing therapies, as well as oncologists and researchers seeking more effective and targeted treatment options.
Features
- Proprietary linker-payload technologies for enhanced ADC specificity
- Focus on targets with strong biological rationale and clinical validation
- Pipeline of differentiated antibody therapeutics, including ADCs
- Development of dual-payload ADCs to overcome resistance to topoisomerase 1 inhibitor ADCs
- Capability to design and engineer therapeutics for oncology and autoimmune diseases
- Precision clinical trials designed to maximize probability of success